{'fraction_non_alphanumeric': 0.014527845036319613, 'fraction_numerical': 0.024213075060532687, 'mean_word_length': 4.830985915492958, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
DMP 266 study opens at Jefferson.


 Dupont Merck announced that its experimental non-nucleoside reverse transcriptase inhibitor DMP 266 has shown viral load reductions to undetectable levels in eighty percent of study subjects. CD4 counts also increased among the study group. Other studies are underway to study DMP 266 at higher dosages and in combination with other drugs. Enrollment information is included.
